Menu
Home Explore People Places Arts History Plants & Animals Science Life & Culture Technology
On this page
Validation and verification (medical devices)

Validation and verification are procedures that ensure that medical devices fulfil their intended purpose. Validation or verification is generally needed when a health facility acquires a new device to perform medical tests.

We don't have any images related to Validation and verification (medical devices) yet.
We don't have any YouTube videos related to Validation and verification (medical devices) yet.
We don't have any PDF documents related to Validation and verification (medical devices) yet.
We don't have any Books related to Validation and verification (medical devices) yet.
We don't have any archived web articles related to Validation and verification (medical devices) yet.

Validation or verification

The main difference between the two is that validation is focused on ensuring that the device meets the needs and requirements of its intended users and the intended use environment, whereas verification is focused on ensuring that the device meets its specified design requirements.

For instance, a regulatory agency (such as CE or FDA) may ensure that a product has been validated for general use before approval. An individual laboratory that introduces such an approved medical device may then not need to perform their own validation, but generally still need to perform verification to ensure that the device works correctly.1

Workflow

Standards

Standards for validation and verification of medical laboratories are outlined in the international standard ISO 15189, in addition to national and regional regulations.2

As per United States federal regulations, the following analytical tests need to be done by a medical laboratory that introduces a new testing device:

Parameter(s)Verification ofFDA-approved deviceValidation of a laboratory-developed test
Accuracy and precisionYes34Yes56
Reportable rangeYes78Yes910
Analytical sensitivityYes11Yes1213
Analytical specificityYes1415
Reference rangeVerification16Establishment17
Carryover effectYes18
Sample/materials stabilityYes19

To establish a reference range, the Clinical and Laboratory Standards Institute (CLSI) recommends testing at least 120 patient samples. In contrast, for the verification of a reference range, it is recommended to use a total of 40 samples, 20 from healthy men and 20 from healthy women, and the results should be compared to the published reference range. The results should be evenly spread throughout the published reference range rather than clustered at one end. The published reference range can be accepted for use if 95% of the results fall within it. Otherwise, the laboratory needs to establish its own reference range.20

See also

References

  1. Roelofsen-de Beer R, Wielders J, Boursier G, Vodnik T, Vanstapel F, Huisman W; et al. (2020). "Validation and verification of examination procedures in medical laboratories: opinion of the EFLM Working Group Accreditation and ISO/CEN standards (WG-A/ISO) on dealing with ISO 15189:2012 demands for method verification and validation". Clin Chem Lab Med. 58 (3): 361–367. doi:10.1515/cclm-2019-1053. hdl:2066/217437. PMID 31714885.{{cite journal}}: CS1 maint: multiple names: authors list (link) https://doi.org/10.1515%2Fcclm-2019-1053 ↩

  2. Roelofsen-de Beer R, Wielders J, Boursier G, Vodnik T, Vanstapel F, Huisman W; et al. (2020). "Validation and verification of examination procedures in medical laboratories: opinion of the EFLM Working Group Accreditation and ISO/CEN standards (WG-A/ISO) on dealing with ISO 15189:2012 demands for method verification and validation". Clin Chem Lab Med. 58 (3): 361–367. doi:10.1515/cclm-2019-1053. hdl:2066/217437. PMID 31714885.{{cite journal}}: CS1 maint: multiple names: authors list (link) https://doi.org/10.1515%2Fcclm-2019-1053 ↩

  3. Stone JA, van der Gugten JG (2023). "Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests". J Mass Spectrom Adv Clin Lab. 28: 82–90. doi:10.1016/j.jmsacl.2023.03.001. PMC 10017411. PMID 36937811. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017411 ↩

  4. "All Common Checklist" (PDF). College of American Pathologists. 2021-09-22. https://rankinbiomed.com/wp-content/uploads/CAP-All-Common-Checklist-06042020-1.pdf ↩

  5. Stone JA, van der Gugten JG (2023). "Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests". J Mass Spectrom Adv Clin Lab. 28: 82–90. doi:10.1016/j.jmsacl.2023.03.001. PMC 10017411. PMID 36937811. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017411 ↩

  6. "All Common Checklist" (PDF). College of American Pathologists. 2021-09-22. https://rankinbiomed.com/wp-content/uploads/CAP-All-Common-Checklist-06042020-1.pdf ↩

  7. Stone JA, van der Gugten JG (2023). "Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests". J Mass Spectrom Adv Clin Lab. 28: 82–90. doi:10.1016/j.jmsacl.2023.03.001. PMC 10017411. PMID 36937811. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017411 ↩

  8. "All Common Checklist" (PDF). College of American Pathologists. 2021-09-22. https://rankinbiomed.com/wp-content/uploads/CAP-All-Common-Checklist-06042020-1.pdf ↩

  9. Stone JA, van der Gugten JG (2023). "Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests". J Mass Spectrom Adv Clin Lab. 28: 82–90. doi:10.1016/j.jmsacl.2023.03.001. PMC 10017411. PMID 36937811. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017411 ↩

  10. "All Common Checklist" (PDF). College of American Pathologists. 2021-09-22. https://rankinbiomed.com/wp-content/uploads/CAP-All-Common-Checklist-06042020-1.pdf ↩

  11. Stone JA, van der Gugten JG (2023). "Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests". J Mass Spectrom Adv Clin Lab. 28: 82–90. doi:10.1016/j.jmsacl.2023.03.001. PMC 10017411. PMID 36937811. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017411 ↩

  12. Stone JA, van der Gugten JG (2023). "Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests". J Mass Spectrom Adv Clin Lab. 28: 82–90. doi:10.1016/j.jmsacl.2023.03.001. PMC 10017411. PMID 36937811. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017411 ↩

  13. "All Common Checklist" (PDF). College of American Pathologists. 2021-09-22. https://rankinbiomed.com/wp-content/uploads/CAP-All-Common-Checklist-06042020-1.pdf ↩

  14. Stone JA, van der Gugten JG (2023). "Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests". J Mass Spectrom Adv Clin Lab. 28: 82–90. doi:10.1016/j.jmsacl.2023.03.001. PMC 10017411. PMID 36937811. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017411 ↩

  15. "All Common Checklist" (PDF). College of American Pathologists. 2021-09-22. https://rankinbiomed.com/wp-content/uploads/CAP-All-Common-Checklist-06042020-1.pdf ↩

  16. Stone JA, van der Gugten JG (2023). "Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests". J Mass Spectrom Adv Clin Lab. 28: 82–90. doi:10.1016/j.jmsacl.2023.03.001. PMC 10017411. PMID 36937811. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017411 ↩

  17. Stone JA, van der Gugten JG (2023). "Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests". J Mass Spectrom Adv Clin Lab. 28: 82–90. doi:10.1016/j.jmsacl.2023.03.001. PMC 10017411. PMID 36937811. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017411 ↩

  18. Stone JA, van der Gugten JG (2023). "Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests". J Mass Spectrom Adv Clin Lab. 28: 82–90. doi:10.1016/j.jmsacl.2023.03.001. PMC 10017411. PMID 36937811. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017411 ↩

  19. Stone JA, van der Gugten JG (2023). "Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests". J Mass Spectrom Adv Clin Lab. 28: 82–90. doi:10.1016/j.jmsacl.2023.03.001. PMC 10017411. PMID 36937811. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017411 ↩

  20. "Reference Ranges". ClinLab Navigator. Retrieved 2023-04-25. http://www.clinlabnavigator.com/reference-ranges.html ↩